| Market Capitalization (Millions $) |
39 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
8 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-17 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
CNS Pharmaceuticals Inc is a biotechnology company focused on the development of novel treatments for central nervous system (CNS) disorders. The company aims to address unmet medical needs in diseases such as glioblastoma multiforme (GBM), an aggressive and difficult to treat form of brain cancer.
CNS Pharmaceuticals is primarily focused on the development of Berubicin, a potential breakthrough therapy for GBM. Berubicin is a potent anthracycline chemotherapy agent that has demonstrated promising results in preclinical studies and has currently entered Phase 1 clinical trials.
The company's mission is to bring innovative and effective therapies to patients suffering from CNS disorders with limited treatment options. CNS Pharmaceuticals is committed to advancing the development of Berubicin and other potential therapies through rigorous scientific research and clinical trials.
Company Address: 2100 West Loop South Houston 77027 TX
Company Phone Number: 946-9185 Stock Exchange / Ticker: NASDAQ CNSP
|
0.66% 